Fortress Biotech, Inc. (FBIO) compared with its closest peers (PLYX, BMEA, ACRV, ALDX, RLYB): P/E 0.9 vs industry 17.0. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $103.68M | — |
| Biomea Fusion, Inc. (BMEA) | $98.58M | -1.0 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV) | $94.59M | -1.2 |
| Aldeyra Therapeutics, Inc. (ALDX) | $91.69M | -9.2 |
| Rallybio Corporation (RLYB) | $89.22M | -0.4 |
| Gain Therapeutics, Inc. (GANX) | $87.29M | -5.3 |
| Adicet Bio, Inc. (ACET) | $85.86M | -0.5 |
| MAIA Biotechnology, Inc. (MAIA) | $84.55M | -2.2 |
| LifeVantage Corporation (LFVN) | $84.02M | 11.6 |
| Dogwood Therapeutics, Inc. (DWTX) | $83.62M | -0.6 |
| Stock P/E | 0.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -96.1% |
| vs Industry | -95.0% |
FBIO overview · FBIO earnings · FBIO financials · FBIO KPIs · FBIO investor relations · FBIO ownership · FBIO filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.